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SUMMARY · Although nonsustained ventricular tachycardia after myocardial infarction may be
associated with an increased risk of sudden cardiac death, there are no clear guidelines as to which is
the most effective management of this arrhythmia. In this paper, we present our experience in the
treatment of patients with asymptomatic nonsustained ventricular tachycardia, prior myocardial in-
farction, and left ventricular ejection fraction <40%, based on electropharmacological testing per-
formed in 130 patients. Eighty-two of them had noninducible, and 48 inducible sustained mono-
morphic ventricular tachycardia. Patients with noninducible ventricular tachycardia were random-
ized to treatment with no antiarrhythmogenic drugs (n=46) or beta-blockers (n=36). Among pa-
tients with inducible ventricular tachycardia, 23 were treated with electropharmacologically guided
drug therapy, and 25 with drugs slowing inducible ventricular tachycardia. During a mean follow-up
period of 24 months, seven patients died suddenly, five survived cardiac arrest, and 12 suffered
nonsudden death. The overall incidence of sudden cardiac death and total mortality were signifi-
cantly higher in patients with inducible than in those with noninducible ventricular tachycardia. The
incidence of sudden cardiac death at 2 years was 33% in patients with inducible and nonsuppressible
ventricular tachycardia, 7% in patients with inducible and electropharmacologically guided therapy,
9% in patients with noninducible ventricular tachycardia treated without drugs, and 8% in patients
with noninducible ventricular tachycardia treated with beta-blockers. In conclusion, patients with
asymptomatic nonsustained ventricular tachycardia, prior myocardial infarction, ejection fraction <40%,
and excluded active ischemia should be submitted to electropharmacological testing. Patients with
noninducible ventricular tachycardia may be followed with no drugs. Patients with inducible and
suppressible ventricular tachycardia may be treated by effective drug if their ejection fraction is higher
than that recorded in the Multicenter UnSustained Tachycardia Trial population. Patients with in-
ducible and nonsuppressible ventricular tachycardia are candidates for cardioverter-defibrillator
implantation, because they are at a high risk of sudden cardiac death.
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Introduction
Although nonsustained ventricular tachycardia (VT)
after myocardial infarction (MI) may be associated with
an increased risk of sudden cardiac death, there are no
clear guidelines as to which is the most effective manage-
ment of this arrhythmia. Over the last ten years, progra-
mmed ventricular stimulation was used by some authors
to guide therapy in such patients, and noninducibility of
sustained monomorphic VT after electropharmacological
testing was considered as a predictor of successful antiar-
rhythmic therapy1-4. Recently, two studies have shown
that patients with asymptomatic nonsustained VT, MI,
low left ventricular ejection fraction, and inducible sus-
tained monomorphic VT have a significantly better clini-
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cal outcome if treated by implantable cardioverter-defi-
brillator than by antiarrhythmic drugs, contesting the
empirical and electrophysiologically guided antiarrhyth-
mic therapy in these patients5,6.
The purpose of this paper is to present our experience
in the treatment of asymptomatic nonsustained VT in pa-
tients after MI, based on the electropharmacological eva-




Study population consisted of 130 consecutive patients
referred to our Department of Arrhythmias for evaluation
of nonsustained VT between March 1989 and March
1995. Criteria for inclusion in the study were as follows:
1) asymptomatic nonsustained VT (duration of >6 beats
to 30 seconds, rate >120 beats/min) documented by am-
bulatory  monitoring or telemetry recordings; 2) a Q-wave
positive myocardial infarction more than 2 months before
entry; 3) left ventricular ejection fraction <40%; and 4) life
expectancy of more than one year. Patients with a history
of sustained VT or ventricular fibrillation (VF), active
myocardial ischemia, functional class IV, or significant co-
morbidity were ecluded from the study.
Left ventricular function was assessed by radionuclide
ventriculography. Active myocardial ischemia was ex-
cluded by clinical evaluation, coronarography (30 pa-
tients), or exercise stress testing (100 patients).
Electrophysiologic and electropharmacologic evaluation
The electrophysiologic study was performed in the
absence of antiarrhythmic therapy for at least ten days. All
patients gave written informed consent. Three to four
quadripolar electrode catheters were introduced percuta-
neously through femoral veins and positioned in the high
right atrium, His bundle area and right ventricular apex.
Five surface electrocardiograms and  three intracardiac re-
cordings were made simultaneously at paper seeds of 25
and 100 mm/s by a Siemens Mingograf 7 recorder. Int-
racardiac pacing was performed at twice diastolic thresh-
old with a pulse duration of 2 ms. Ventricular stimulation
was performed at the apex and outflow tract of the right
ventricle using three drive ventricular cycles (500, 400 and
350 ms) and up to three extrastimuli. The end point of
stimulation was the induction of sustained monomorphic
VT, or completion of the entire stimulation protocol with-
out induction of this arrhythmia.
In patients with baseline inducible sustained mono-
morphic VT, the protocol of ventricular stimulation was
repeated after intravenous loading of sotalol (1.5 mg/kg/
15 min) or amiodarone (10 mg/kg/10 min). If the induc-
tion of sustained monomorphic VT was suppressed by one
of these antiarrhythmic agents, the patient was longterm
treated with the respective drug per os. If the induction of
sustained monomorphic VT was not suppressed by these
antiarrhythmic agents, the patient was treated with the
drug that made the induced tachycardia best tolerated.
Patients with noninducible sustained monomorphic VT
were randomized to be off drugs or to take beta-blockers.
The following definitions were used with regard to the
electrophysiologic study: sustained monomorphic VT was
defined as having a uniform beat-to-beat QRS morphol-
ogy lasting for more than 30 seconds, rate >120 beats/min,
or requiring earlier termination by external electroshock
because of hemodynamic compromise. Polymorphic VT
was defined as having a variable QRS morphology.
Follow-up
All patients were prospectively followed at our Ar-
rhythmia Center every 6 months. Each control included
history, physical examination, 12-lead electrocardiogram,
and Holter monitoring. The end points of the follow-up
were the occurrence of VF successfully resolved by exter-
nal electroshock and resuscitation, sudden death, and
nonsudden cardiac death.
Sudden cardiac death was defined as a death due to
documented ventricular tachyarrhythmia, or death which
occurred within minutes of the onset of symptoms, or du-
ring sleep in a previously stable patient. On statistical ana-
lysis, patients with resuscitated VF were also classified as
having sudden cardiac death. Nonsudden cardiac deaths
were those due to acute MI or congestive heart failure.
Statistical analysis
Data are given as mean ± 1 standard deviation. Stu-
dent’s t-test was used to assess difference in means, and
χ2-test for frequency data analysis. The incidence of sud-
den cardiac death and cardiac mortality was determined
using Kaplan-Meier method. Differences between the
groups and subgroups were considered statistically signifi-
cant at p<0.05.
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Results
Patient characteristics
According to the results of baseline electrophysiolo-
gic evaluation, 130 study patients were divided into two
groups. Eighty-two (63%) patients had noninducible
sustained monomorphic VT. In six of them, nonsustai-
ned polymorphic VT lasting for 6 to 12 beats was in-
duced, but these findings were considered as nonclinical
responses. The remaining 48 (37%) patients had induc-
ible sustained monomorphic VT. Single ventricular
extrastimuli were required for induction of tachycardia
in four, two extrastimuli in 16, and three extrastimuli in
28 patients. The mean cycle length of the induced VT
was 300 ± 50 ms.
Clinical characteristics of patients with noninducible
and inducible sustained monomorphic VT are presented
in Table 1. There were no differences between the groups
according to gender, age, and localization of MI. Patients
with noninducible VT had a slightly higher left ventricular
ejection fraction, but the difference did not reach statis-
tical significance. On electrocardiographic monitoring,
there were no between-group differences according to the
frequency of premature ventricular beats or mean dura-
tion of nonsustained VT.
Table 1. Clinical characteristics of 130 patients with
noninducible and inducible monomorphic ventricular tachycardia
Noninducible VT Inducible VT
(n=82) (n=48)
Age (yrs) 61±9 62±10
Male gender (%) 83 82
Localization
of MI (%)
· anteroseptal 26 27
· anterior 26 21
· inferior 43 42
LVEF (%) 37 (33-39) 35 (30-39)
PVB (h) 118±26 124±100
Episodes of NSVT
(No./24 h) 26±16 28±10
Mean number of
NSVT beats 12 10
MI=myocardial infarction; LVEF=left ventricular ejection fraction;
PVB=premature ventricular beat; NSVT=nonsustained ventricular ta-
chycardia
Patient treatment
The treatment of patients was assigned on the basis
of electropharmacologic testing (Fig. 1). Eighty-two pa-
tients with noninducible sustained monomorphic VT
were randomized in two subgroups. Forty-six (56%) of
them were administered no medicamentous therapy, and
36 (44%) were treated with beta-blockers. Among 48 pa-
tients with inducible sustained monomorphic VT, an ef-
fective drug was found by electrophysiologic testing in 23
(48%) patients. In this subgroup, 17 patients were trea-
ted with amiodarone, and six with sotalol. The 25 (52%)
patients in whom inducible sustained monomorphic VT
persisted were treated with a drug that made induced ta-
chycardia slowest and hemodynamically more tolerable.
In this subgroup, 17 patients were treated with amioda-
rone and eight with sotalol.
Follow-up
During a mean follow-up period of 24 ± 6 months,
eight patients died suddenly, and four were successfully
resuscitated from VF (Fig. 1). The overall incidence of
sudden cardiac death at 2 years was 8% in patients with
noninducible VT, and 21% in patients with inducible sus-
tained monomorphic VT (p<0.05). Ten patients suffered
nonsudden cardiac death (three from acute MI and seven
from congestive heart failure), and two noncardiac death.
The overall mortality rate at 2 years was 19% in patients
with noninducible VT, and 39% in those with inducible
VT (p<0.05) (Table 2).
Table 2. Cumulative survival in 130 patients with
noninducible and inducible monomorphic ventricular tachycardia
Noninducible VT Inducible VT
(n=82) (n=48)
% %
6 months 95 91
12 months 89 80
18 months 82 74
24 months 81 61
p<0.05
The incidence of sudden cardiac death according to
assigned therapy in the subgroups of noninducible and
inducible sustained monomorphic VT is presented in
Figs. 2 and 3, respectively. Among patients with nonindu-
cible sustained monomorphic VT, significant arrhythmic
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events (2 VF and 1 sudden cardiac death) occurred in
three of 46 patients treated with no drugs, and in two of
36 patients treated with beta-blockers, yielding a 2-year
incidence of sudden cardiac death of 9% and 8%, respec-
tively. There was a significant difference in the incidence
of sudden cardiac death between the two subgroups of
patients with inducible sustained monomorphic VT. Only
one of 23 patients with inducible and suppressible VT
(receiving amiodarone) died suddenly at 6 months of fol-
low-up, yielding a 2-year incidence of sudden cardiac
death of 7%. In contrast, six of 25 patients with induc-























Fig. 1. Flow chart of treatment and outcome in 130 patients with noninducible and inducible sustained monomorphic ventricular tachy-
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Fig. 2. Actuarial incidence of sudden cardiac death or cardiac arrest
in patients with noninducible sustained monomorphic ventricular
tachycardia with regard to assigned therapy.
Fig. 3. Actuarial incidence of sudden cardiac death or cardiac arrest
in patients with inducible monomorphic sustained ventricular ta-
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p < 0.05
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events (3 VF and 4 sudden cardiac death) during the
follow-up, yielding a 2-year sudden cardiac death inci-
dence of 33% (p<0.05).
Discussion
At the beginning of the new millennium, the manage-
ment of patients with asymptomatic nonsustained VT and
MI is still one of the continuing problems for modern phy-
sicians and cardiologists, because these patients may be at
risk of sudden cardiac death due to VF. Several studies were
performed to determine whether such patients might ben-
efit from electrophysiologic testing1,3,4,8.The rationale has
been that electrophysiologic testing identifies patients at a
high risk of future arrhythmic events, and that it may se-
lect those with successful drug therapy. In spite of several
shortcomings, the published studies seem to demonstrate
that patients with noninducible sustained VT have a low
rate of sudden cardiac death and do not appear to require
antiarrhythmic therapy. The risk of sudden cardiac death
in these patients is even lower when they have a left ven-
tricular ejection fraction higher than 40%9,10. However, the
ability of antiarrhythmic therapy guided by electrophar-
macologic testing to prevent sudden cardiac death in this
population has not been proven, although some studies
suggest that electrophysiologically guided antiarrhythmic
therapy in this population is associated with a lower rate of
sudden cardiac death compared with empirical therapy3,4,8.
Our study confirmed the results of previous investi-
gations that electrophysiologic testing may be useful in
risk stratification and management of patients with MI
who have asymptomatic nonsustained VT and left ven-
tricular ejection fraction lower than 40%. The inducibil-
ity of sustained monomorphic VT during baseline electro-
physiologic study was shown to be an independent pre-
dictor of future patient’s outcome. Patients with this find-
ing had a significantly higher overall incidence of sudden
cardiac death and total mortality at 2 years than those with
noninducible VT (p<0.05), suggesting that such patients
require a more aggressive therapeutic approach for preven-
tion of sudden cardiac death. We examined the value of
noninducibility of sustained monomorphic VT by ran-
domization of these patients to the treatment with no
antiarrhythmic drugs or with beta-blockers. The incidence
of arrhythmic events in these patients at 2 years was lower
(9%) than in several groups of historical controls with un-
treated spontaneous nonsustained VT (17%)11-13. Howe-
ver, there was no statistically significant difference in the
incidence of sudden cardiac death between untreated pa-
tients and patients treated with beta-blockers at 2 years
(9% versus 8%). It means that this patient subgroup may
be followed without antiarrhythmic drug therapy. Simi-
lar data were obtained in the study of Schmitt et al., where
the 2-year incidence of sudden cardiac death in patients
treated mostly with beta-blockers was 8%10. A positive
electrophysiologic testing at baseline evaluation also ap-
peared to be of value for the patient’s management. Pa-
tients with inducible sustained monomorphic VT that was
suppressed by antiarrhythmic therapy during electrophar-
macologic testing had a 7% rate of sudden cardiac death,
whereas those with persistently inducible VT had a 33%
rate of sudden cardiac death at 2 years (p<0.05), suggest-
ing that the results of electropharmacologic testing are
predictive of outcome in these patients. The higher over-
all mortality in patients with inducible sustained mono-
morphic VT was probably associated with the higher in-
cidence of sudden cardiac death in this group, because the
incidence of nonsudden cardiac death was proportional in
patients with inducible and noninducible VT.
Two recent studies contest the value of empirical5,6 and
electrophysiologically guided antiarrhythmic drug therapy6
in populations comparable with our study population
(Table 3). The Multicenter Automatic Defibrillator Im-
plantation Trial (MADIT) evaluated the role of cardio-
verter-defibrillator (ICD) as prophylaxis in patients with
asymptomatic nonsustained VT, prior MI, low left ven-
tricular ejection fraction (<35%), and inducible and
nonsuppressible sustained monomorphic VT. The end
point of the trial was overall mortality. After a mean fol-
low-up period of 27 months, ICD was associated with a
54% reduction of all-cause mortality compared with con-
ventional antiarrhythmic therapy (75% amiodarone). The
impact of this study was so strong that the current selec-
tion criteria for ICD therapy reflect exactly the results of
the trial. The Multicenter UnSustained Tachycardia Trial
(MUSST) studied a nearly identical group of patients
(asymptomatic nonsustained VT, prior MI, mean left ven-
tricular ejection fraction of 30%, and inducible sustained
monomorphic VT). They were randomly assigned to recei-
ve electrophysiologically guided antiarrhythmic drug
therapy, ICD, or no therapy (Table 3). The risk of cardiac
arrest among patients receiving an ICD was significantly
lower than that among patients on drug therapy. Moreover,
the mortality reduction for all causes for patients with ICD
versus patients with no drug, drugs or electrophysiologically
guided drug therapy was 51%. So, MUSST has established
some important clues in identifying patients with prior MI
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at high risk: high degree left ventricular dysfunction,
nonsustained VT on Holter recording, and inducibility of
VT at electrophysiologic study. In such a population, ICD
implantation has significant benefit.
Although our study was designed in a different fash-
ion than MUSST, there are some statements that are com-
mon to both studies. In the population presented, the
electrophysiologic testing did not lose its role in risk strati-
fication. It was definitely shown that patients without in-
ducibility of VT had a significantly lower risk of sudden
cardiac death and overall mortality than similar patients
with inducible sustained monomorphic VT14. Accord-
ingly, the latter group of patients need a more extensive
therapeutic approach such as ICD implantation. Our re-
sults of electrophysiologically guided antiarrhythmic the-
rapy differ from those reported from the MUSST study.
These differences may be explained by the smaller num-
ber of patients, shorter follow-up, and higher mean left
ventricular ejection fraction (35% versus 30%) in our study,
and lower use of amiodarone (23% versus 74%) in the
MUSST study.
Limitations
A major limitation of our study was that the patients
treated by electropharmacologically guided antiarrhyth-
mic therapy had no control group administered placebo.
It was therefore impossible to demonstrate that the mana-
gement based on electropharmacologic testing improved
the outcome in these patients. This shortcoming is even
more pronounced after MUSST study, which found no
benefit of electrophysiologically guided antiarrhythmic
therapy. Another limitation of the present study was the
relatively small number of patients in the subgroups with
inducible and noninducible VT, making difficult any defi-
nite recommendations for the management of these pa-
tients. Finally, our study was terminated before the MA-
DIT criteria for ICD implantation have been accepted.
Thus, we could not offer this therapeutic option to our pa-
tients with inducible and nonsuppressible sustained mo-
nomorphic VT.
Clinical implications
Patients with asymptomatic nonsustained VT, prior
MI, and left ventricular ejection fraction lower than 40%,
in whom active myocardial ischemia is excluded, should
be considered appropriate candidates for electrophysio-
logic testing. Based on the results of this testing, patients
with noninducible sustained monomorphic VT may be
followed up without antiarrhythmic drug therapy, because
their incidence of sudden cardiac death is low. In this sub-
group of patients, beta-blockers did not reduce the inci-
dence of sudden cardiac death. Patients with inducible
sustained monomorphic VT which proves nonsuppres-
sible during electropharmacologic testing, are candidates
for ICD therapy. According to MUSST study, patients
with inducible and suppressible sustained VT during
electropharmacologic testing should also be considered for
ICD implantation. However, our experience suggests that
electropharmacologically guided antiarrhythmic therapy
is useful in patients in whom the mean left ventricular eje-
Table 3. Crude survival rates in MADIT and MUSST
        MADIT                        MUSST
            ICD           AAR           ICD            No AAR   EP-g AAR
No. of patients 95 101 167 353 184
Death 15 39 35 158 97
Mortality (%) 15.8 38.6 21 44.8 52.7
p value                      0.009     0.001
(ICD vs  AAR) (ICD vs  No AAR, ICD vs  EP-g)
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ction fraction is greater than in the MUSST population.
Patients with left ventricular ejection fraction >40% sho-
uld also be recommended for electrophysiologic evalua-
tion and subsequent therapy, if they have another risk fac-
tor such as positive late potentials or depressed heart rate
variability.
References
1. BUXTON AE, MARCHLINSKI F, FLORES BT, MILLER JM,
DOHERTY JU, JOSEPHSON ME. Nonsustained ventricular ta-
chycardia in patients with coronary artery disease: role of electro-
physiologic study. Circulation 1987;75:1178-85.
2. KLEIN RC, MACHELL C. Use of electrophysiologic testing in
patients with nonsustained ventricular tachycardia: prognostic and
therapeutic implications. J Am Coll Cardiol 1989;14:155-61.
3. WILBER DJ, OLSHANSKY B, MORAN JF, SCANLON PJ.
Electrophysiologic testing and nonsustained ventricular tachycar-
dia: use and limitations in patients with coronary artery disease and
impaired ventricular function. Circulation 1990;82:350-8.
4. KADISH A, SCHMALTZ S, CALKINS H, MORADY F. Man-
agement of nonsustained ventricular tachycardia guided by elec-
trophysiological study. PACE Pacing Clin Electrophysiol 1993;16
(Part I):1037-50.
5. MOSS AJ, HALL WJ, CANNOM DS, DAUBERT JP, HIG-
GINS SL, KLEIN H, LEVINE JH, SAKSENA S, WALDO AL,
WIBER DV, BROWN MW, HEO M, for the Multicenter Au-
tomatic Defibrillator Implantation Trial investigators. Improved
survival with an implanted defibrillator in patients with coronary
disease at high risk for ventricular arrhythmia. N Engl J Med
1996;335:1933-40.
6. BUXTON AE, LEE KI, FISHER JD, JOSEPHSON ME,
PRYSTOWSKY EN, HAFLEY G, for the Multicenter Unsus-
tained Tachycardia Trial investigators. A randomized study of the
prevention of sudden death in patients with coronary artery disease.
N Engl J Med 1999;341:1882-90.
7. PETRAÆ D, RADIÆ B, VUKOSAVIÆ –. Therapeutic approach
to asymptomatic nonsustained ventricular tachycardia after myo-
cardial infarction (abstract). PACE Pacing Clin Electrophysiol
1999;22 (Part II):A90.
8. MANOLIS AS, ESTES M. Value of programmed ventricular sti-
mulation in the evaluation and management of patients with non-
sustained ventricular tachycardia associated with coronary artery
disease. Am J Cardiol 1990;65:201-5.
9. HAMMILI SC, TRUSTY JM, WOOD DL, BAILEY KR,
VATTEROTT PJ, OSBORN MJ, HOLMES DR, GERSH BJ.
Influence of ventricular function and presence or absence of coro-
nary artery disease on results of electrophysiologic testing for as-
ymptomatic nonsustained ventricular tachycardia. Am J Cardiol
1990;65:722-8.
10. SCHMITT H, HURST T, COCH M, KILLAT H, WUNN B,
WALDECKER B. Nonsustained asymptomatic ventricular tachy-
cardia in patients with coronary artery disease: prognosis and in-
cidence of sudden death of patients who are noninducible by elec-
trophysiological testing. PACE Pacing Clin Electrophysiol
2000;23:1220-5.
11. BIGGER JT, FLEISS JL, KLEIGER R, MILLER JP, ROLINT-
ZKY LM, and the Multicenter Postinfarction Research Group.
The relationships among ventricular arrhythmias, left ventricular
dysfunction, and mortality in the 2 years after myocardial infarc-
tion. Circulation 1984;69:250-8.
12. MUKHARJI J, RUDE RE, POOLE WK, GUSTAFSON N,
THOMAS LJ, STRAUSS HW, JAFFE AS, MÜLLER JE, ROB-
ERTS R, RAABE DS, CROF CH, PASSAMANI E, BRAUN-
WALD E, WILLERSON JT, and the MILIS Study Group. Risk
factors for sudden cardiac death following acute myocardial infarc-
tion (two-year follow-up). Am J Cardiol 1984;54:31-6.
13. MOSS AJ, BIGGER JT, ODOROFF C. Postinfarct risk stratifi-
cation. Prog Cardiovasc Dis 1987;29:389-412.
14. BUXTON AE, KERRY LL, DiCARLO L, GOLD MR, GRE-
ER GS, PRYSTOWSKY EN, O’TOOLE MF, TANG A, FI-
SHER JD, COROMILAS J, TALAIÆ M, HAFLEY G, for the
Multicenter Unsustained Tachycardia Trial investigators. Electro-
physiologic testing to identify patients with coronary artery disease
who are at risk for sudden death. N Engl J Med 2000;342:1937-45.
D. PetraË et al. Therapeutic approach to nonsustained VT
38 Acta clin Croat, Vol. 40, No. 1, 2001
Saæetak
TERAPIJSKI PRISTUP U BOLESNIKA S ASIMPTOMATSKOM NEPOSTOJANOM VENTRIKULSKOM
TAHIKARDIJOM NAKON INFARKTA MIOKARDA
D. PetraË, B. RadiÊ, H. PintariÊ i –. VukosaviÊ
Premda asimptomatska nepostojana ventrikulska tahikardija nakon infarkta miokarda moæe biti povezana s rizikom od nagle
srËane smrti, nema jasnih smjernica kako najdjelotvornije zbrinjavati ovu aritmiju. Prikazujemo na¹a iskustva u lijeËenju bolesnika
s asimptomatskom nepostojanom ventrikulskom tahikardijom, prethodnim infarktom miokarda i ejekcijskom frakcijom lijeve
klijetke <40%, koje se temelji na elektrofarmakolo¹kom testiranju. Elektrofarmakolo¹ko testiranje provedeno je u 130 bolesnika,
od kojih je 82 imalo neizazvanu, a 48 izazvanu postojanu monoformnu ventrikulsku tahikardiju. Od 82 bolesnika s neizazvanom
ventrikulskom tahikardijom, 46 ih je randomizirano na terapiju bez antiaritmika, a 36 na beta-blokatore. Od 48 bolesnika s
izazvanom ventrikulskom tahikardijom, 23 ih je lijeËeno elektrofarmakolo¹ki voðenim lijekovima, a 25 lijekovima koji su usporavali
izazvanu ventrikulsku tahikardiju. Za vrijeme praÊenja kroz 24 mjeseca sedmoro je bolesnika umrlo naglom smrÊu, petoro je
preæivjelo srËani arest, a 12 je umrlo nenaglom srËanom smrÊu. Sveukupna uËestalost nagle srËane smrti i ukupna smrtnost bile
su znaËajno vi¹e u bolesnika s izazvanom od onih u bolesnika s neizazvanom ventrikulskom tahikardijom. Dvogodi¹nja uËestalost
nagle srËane smrti bila je 33% u bolesnika s izazvanom i nesupresibilnom ventrikulskom tahikardijom, 7% u bolesnika s izazvanom
ventrikulskom tahikardijom i elektrofarmakolo¹ki voðenom terapijom, 9% u bolesnika s neizazvanom ventrikulskom tahikardijom
praÊenim bez antiaritmika i 8% u bolesnika s neizazvanom ventrikulskom tahikardijom lijeËenim beta-blokatorima. ZakljuËujemo
da se bolesnici s asimptomatskom nepostojanom ventrikulskom tahikardijom, prethodnim infarktom miokarda, ejekcijskom
frakcijom <40% i iskljuËenom aktivnom ishemijom trebaju podvrgnuti elektrofarmakolo¹kom testiranju. Bolesnici s neizazvanom
ventrikulskom tahikardijom mogu se pratiti bez lijekova. Bolesnici s izazvanom i supresibilnom ventrikulskom tahikardijom mogu
se lijeËiti djelotvornim lijekom, ako je njihova ejekcijska frakcija veÊa od one kod populacije iz studije MUSST. Zbog visokog
rizika od nagle srËane smrti, bolesnici s izazvanom i nesupresibilnom ventrikulskom tahikardijom kandidati su za ugradnju
kardioverter-defibrilatora.
KljuËne rijeËi: Infarkt miokarda, komplikacije; Infarkt miokarda, terapija; Tahikardija, ventrikulska, terapija
